This small leucine-rich proteoglycan may inhibit tumor cell growth, migration, angiogenesis and metastasis [25, 26] by interaction with different receptor tyrosine kinases such as EGF [27, 28], other erbB family members [29], c-Met [30] and IGF-1R [31] and upregulation of p21WAF1/CIP1 (p21) via a p-53 independent pathway [32]. The gene discussed is EGFR; the disease is neoplasm.